BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

477 related articles for article (PubMed ID: 30515553)

  • 1. Self-targeted knockdown of CD44 improves cisplatin sensitivity of chemoresistant non-small cell lung cancer cells.
    Quan YH; Lim JY; Choi BH; Choi Y; Choi YH; Park JH; Kim HK
    Cancer Chemother Pharmacol; 2019 Mar; 83(3):399-410. PubMed ID: 30515553
    [TBL] [Abstract][Full Text] [Related]  

  • 2. CD44 inhibition attenuates EGFR signaling and enhances cisplatin sensitivity in human EGFR wild‑type non‑small‑cell lung cancer cells.
    Yin J; Zhang H; Wu X; Zhang Y; Li J; Shen J; Zhao Y; Xiao Z; Lu L; Huang C; Zhang Z; Du F; Wu Y; Kaboli PJ; Cho CH; Yuan D; Li M
    Int J Mol Med; 2020 Jun; 45(6):1783-1792. PubMed ID: 32236608
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Crosstalk between Raf-MEK-ERK and PI3K-Akt-GSK3β signaling networks promotes chemoresistance, invasion/migration and stemness via expression of CD44 variants (v4 and v6) in oral cancer.
    Kashyap T; Pramanik KK; Nath N; Mishra P; Singh AK; Nagini S; Rana A; Mishra R
    Oral Oncol; 2018 Nov; 86():234-243. PubMed ID: 30409306
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Hyaluronan-CD44 interaction promotes HPV 16 E6 oncogene-mediated oropharyngeal cell carcinoma survival and chemoresistance.
    Bourguignon LYW; Earle C; Shiina M
    Matrix Biol; 2019 May; 78-79():180-200. PubMed ID: 30077625
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Combination treatment of FTY720 and cisplatin exhibits enhanced antitumour effects on cisplatin-resistant non-small lung cancer cells.
    Li Y; Hu T; Chen T; Yang T; Ren H; Chen M
    Oncol Rep; 2018 Feb; 39(2):565-572. PubMed ID: 29207165
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Elevated expression of BIRC6 protein in non-small-cell lung cancers is associated with cancer recurrence and chemoresistance.
    Dong X; Lin D; Low C; Vucic EA; English JC; Yee J; Murray N; Lam WL; Ling V; Lam S; Gout PW; Wang Y
    J Thorac Oncol; 2013 Feb; 8(2):161-70. PubMed ID: 23287853
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Overcoming cisplatin resistance in non-small cell lung cancer with Mad2 silencing siRNA delivered systemically using EGFR-targeted chitosan nanoparticles.
    Nascimento AV; Singh A; Bousbaa H; Ferreira D; Sarmento B; Amiji MM
    Acta Biomater; 2017 Jan; 47():71-80. PubMed ID: 27697601
    [TBL] [Abstract][Full Text] [Related]  

  • 8. ZNF300 promotes chemoresistance and aggressive behaviour in non-small-cell lung cancer.
    Yu S; Ao Z; Wu Y; Song L; Zhang P; Li X; Liu M; Qian P; Zhang R; Li X; Chen Y; Wang X; Wang X; Ruan X; Qian G; Ji F
    Cell Prolif; 2020 Nov; 53(11):e12924. PubMed ID: 33078469
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Targeting MALAT1 induces DNA damage and sensitize non-small cell lung cancer cells to cisplatin by repressing BRCA1.
    Huang J; Lin C; Dong H; Piao Z; Jin C; Han H; Jin D
    Cancer Chemother Pharmacol; 2020 Nov; 86(5):663-672. PubMed ID: 33030583
    [TBL] [Abstract][Full Text] [Related]  

  • 10. CXCR4 promotes cisplatin-resistance of non-small cell lung cancer in a CYP1B1-dependent manner.
    Xie S; Tu Z; Xiong J; Kang G; Zhao L; Hu W; Tan H; Tembo KM; Ding Q; Deng X; Huang J; Zhang Q
    Oncol Rep; 2017 Feb; 37(2):921-928. PubMed ID: 27922681
    [TBL] [Abstract][Full Text] [Related]  

  • 11. EHD1 confers resistance to cisplatin in non-small cell lung cancer by regulating intracellular cisplatin concentrations.
    Gao J; Meng Q; Zhao Y; Chen X; Cai L
    BMC Cancer; 2016 Jul; 16():470. PubMed ID: 27411790
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Knockdown of lncRNA-XIST enhances the chemosensitivity of NSCLC cells via suppression of autophagy.
    Sun W; Zu Y; Fu X; Deng Y
    Oncol Rep; 2017 Dec; 38(6):3347-3354. PubMed ID: 29130102
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Long non‑coding RNA AK001796 contributes to cisplatin resistance of non‑small cell lung cancer.
    Liu B; Pan CF; Ma T; Wang J; Yao GL; Wei K; Chen YJ
    Mol Med Rep; 2017 Oct; 16(4):4107-4112. PubMed ID: 29067469
    [TBL] [Abstract][Full Text] [Related]  

  • 14. miR-202 Enhances the Anti-Tumor Effect of Cisplatin on Non-Small Cell Lung Cancer by Targeting the Ras/MAPK Pathway.
    Sun W; Ping W; Tian Y; Zou W; Liu J; Zu Y
    Cell Physiol Biochem; 2018; 51(5):2160-2171. PubMed ID: 30522099
    [TBL] [Abstract][Full Text] [Related]  

  • 15. MiR-219a-5p enhances cisplatin sensitivity of human non-small cell lung cancer by targeting FGF9.
    Rao C; Miao X; Zhao G; Zhang C; Shen H; Dong C; Yang M
    Biomed Pharmacother; 2019 Jun; 114():108662. PubMed ID: 30999114
    [TBL] [Abstract][Full Text] [Related]  

  • 16. CD44 variant-dependent regulation of redox balance in EGFR mutation-positive non-small cell lung cancer: A target for treatment.
    Kawano Y; Iwama E; Tsuchihashi K; Shibahara D; Harada T; Tanaka K; Nagano O; Saya H; Nakanishi Y; Okamoto I
    Lung Cancer; 2017 Nov; 113():72-78. PubMed ID: 29110853
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Silencing tumor-intrinsic CD73 enhances the chemosensitivity of NSCLC and potentiates the anti-tumoral effects of cisplatin: An in vitro study.
    Baghbani E; Noorolyai S; Rahmani S; Shanehbandi D; Shadbad MA; Aghebati-Maleki L; Mokhtarzadeh A; Brunetti O; Fasano R; Silvestris N; Baradaran B
    Biomed Pharmacother; 2022 Jan; 145():112370. PubMed ID: 34862113
    [TBL] [Abstract][Full Text] [Related]  

  • 18. All-trans retinoic acid reduces cancer stem cell-like cell-mediated resistance to gefitinib in NSCLC adenocarcinoma cells.
    Yao W; Wang L; Huang H; Li X; Wang P; Mi K; Cheng J; Liu H; Gu C; Huang L; Huang J
    BMC Cancer; 2020 Apr; 20(1):315. PubMed ID: 32293355
    [TBL] [Abstract][Full Text] [Related]  

  • 19. EGCG inhibits CSC-like properties through targeting miR-485/CD44 axis in A549-cisplatin resistant cells.
    Jiang P; Xu C; Chen L; Chen A; Wu X; Zhou M; Haq IU; Mariyam Z; Feng Q
    Mol Carcinog; 2018 Dec; 57(12):1835-1844. PubMed ID: 30182373
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Curcumin downregulates p38 MAPK-dependent X-ray repair cross-complement group 1 (XRCC1) expression to enhance cisplatin-induced cytotoxicity in human lung cancer cells.
    Tung CL; Jian YJ; Chen JC; Wang TJ; Chen WC; Zheng HY; Chang PY; Liao KS; Lin YW
    Naunyn Schmiedebergs Arch Pharmacol; 2016 Jun; 389(6):657-66. PubMed ID: 27026405
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 24.